Oncotelic's Joint Venture Sapu Nano Receives Approval for Phase 1 Trial of Injectable Everolimus for Breast Cancer
Sapu Nano's approval to begin Phase 1 clinical trials for an injectable version of Everolimus represents a potential breakthrough in breast cancer treatment by enabling full drug absorption compared to the oral version's limited 10% bioavailability.
Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced that its joint venture Sapu Nano has received approval from Australia's Human Research Ethics Committee to begin patient enrollment for a Phase 1 clinical trial of Sapu003, an injectable formulation of Everolimus for breast cancer treatment. This development marks a significant advancement in cancer therapeutics as it addresses the major limitation of the currently approved oral version of Everolimus, marketed as Afinitor, which has only about 10% absorption rate when taken orally.
The injectable formulation utilizes Sapu Nano's proprietary Deciparticle technology, which allows for intravenous delivery and full drug absorption into the bloodstream. This technological approach could potentially revolutionize the treatment landscape for breast cancer patients by improving drug efficacy and providing longer-lasting disease control. Preclinical data already suggests that this method may offer superior efficacy compared to the oral version, though human trials will be crucial for validation.
The Phase 1 trial will primarily focus on determining the optimal dosing regimen for future studies, including potential Phase 3 trials. This initial study phase represents a critical step in the drug development process, as establishing proper dosing parameters is essential for both safety and efficacy in subsequent larger-scale trials. The full details of the announcement can be viewed in the official press release available at https://ibn.fm/NoIQt.
For investors and stakeholders following Oncotelic's progress, the latest news and updates relating to OTLC are available in the company's newsroom at https://ibn.fm/OTLC. The successful development of Sapu003 could have substantial implications for breast cancer treatment protocols worldwide, particularly for patients who have not responded adequately to existing therapies. The injectable formulation's potential to provide improved outcomes represents an important advancement in oncology care.
The approval from Australia's regulatory body underscores the global nature of pharmaceutical development and the importance of international collaboration in advancing cancer treatments. As breast cancer remains one of the most prevalent cancers affecting women globally, any improvement in treatment efficacy and patient outcomes carries significant public health importance. The trial's success could potentially lead to new standards of care and improved survival rates for patients battling this disease.